Drage kolege,

Obavještavam Vas da se simpozijum "Prvi hematološki dani RS" sa međunarodnim učešćem održava od 03. - 05. 12. 2021. godine, u hotelu Termag, na Jahorini. Na ovom simpozijumu svoje učešće potvrdili su eminentni stručnjaci iz oblasti hematologije zemalja u okruženju: prof.dr Igor Aurer, doc. dr Sandra Kinda, prof. dr Rajko Kušec, prof. dr Samo Zver, prof. dr Darko Antić, prof. dr Biljana Mihaljević, prof. dr Dragana Stamatović, doc. dr Jelena Bila i dr...
Nadam se da ćete naći načina i vremena, da uzmete aktivnog učešća u radu simpozijuma. Za sve dodatne informacije, stojim Vam na raspolaganju. Radujem se našem i viđenju i druženju.

Puno Vas pozdravljam,

Predsjednik Udruženja hematologa RS,

prof. dr Sandra Hotić-Lazarević

Prvo obavještenje

Prijava učešća

27-29 September 2021

https://2021.esidmeeting.org/

Secondary immunodeficiencies become more and more common and widespread as they develop in the course of numerous diseases and result from a variety of therapeutic conditions. ESID 2021 is a unique multidisciplinary symposium bringing together professionals from different fields to share their expertise in the treatment and management of acquired immunodeficiencies.

Submit your research before 1 June 2021 and make an impact. Progress is in your hands.

For more information, please visit the Symposium website - https://2021.esidmeeting.org/

Dear colleagues,
Aware that the place of hematology patients in national vaccination strategies is of increasing concern to many of you, we want to inform you that EHA has published two statements on its website:
• Recommendations for COVID-19 vaccination in patients with hematologic cancer (LINK)
• Recommendations for COVID-19 vaccination in patients with non-malignant diseases (LINK)

We would encourage you to share these with the health authorities in your country and urge them to:
1. Prioritize the vaccination of patients with hematologic malignancies.
2. Take into account the recommendations for specific groups of patients with non-malignant blood disorders.

Due to scarcity of data, no blanket vaccination strategy can be recommended for patients with non-malignant hematological diseases. EHA’s Scientific Working
Groups will be updating these recommendations once more evidence is available.
Patient-friendly versions of both statements are being prepared by the patient organizations and will be published on the EHA website soon.
Sincerely,

Prof. John Gribben Prof. Elizabeth Macintyre
President President-elect